Dr Colin Story joined UKI2S in November 2023 as an advisory board member.

Dr Story has a rich history in Business Development across Engineering Biology organisations. He began his career at GE Healthcare, progressing through Product Development and Project Management roles to head a global commercial role with full P&L accountability for a £20 million product portfolio.

In 2005 he joined Isis Innovation Ltd, establishing a Business Development team to manage over 200 medical science innovations emanating from Oxford University.. In 2011 he was invited to join OrganOx Ltd as Operations Director, seeing the business take its class III medical device from prototype through to successful completion of first in human clinical trials. Dr Story then co-founded OxSonics in 2013 and served as CEO from January 2014 through to January 2022. Under his leadership, a total of £25m was raised across three financing rounds, and OxSonics’ proprietary ‘SonoTran’ platform technology transitioned into clinical use. He built out the executive team of 30 and the board. Dr Story currently holds the position of Non-Executive Director of Hox Therapeutics Limited, a biotechnology company focussed on the treatment of Prostate Cancer as well as having joined BetaGlue Technologies SpA as CEO and board director in February 2023.